MorphoSys Stock

MorphoSys FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of MorphoSys (MOR.DE) as of Aug 17, 2026 is 157.44 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 244.04 % — a change of -35.49% (lower).

FCF Conversion

157.44 %

YoY

-35.49%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of MorphoSys is 2026 157.44 % . FCF Conversion Rate (FCF/EBITDA) of MorphoSys was 2025 244.04 % . It decreases by -35.49% lower compared to the previous year.
Access this data via the Eulerpool API

MorphoSys Stock analysis

What does MorphoSys do? MorphoSys AG is a biotech company based in Planegg near Munich, Germany, founded in 1992. The company specializes in the discovery and development of therapeutic antibodies and operates worldwide. MorphoSys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MorphoSys stock

FCF Conversion Rate (FCF/EBITDA) of MorphoSys is 157.44 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of MorphoSys changed from 244.04 % to 157.44 %, representing a -35.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) MorphoSys since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s MorphoSys with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — MorphoSys

All Key Metrics — MorphoSys